FDA Requests Ranitidine (Zantac) Products Be Removed from the Market
The U.S. Food and Drug Administration (the “FDA”) announced today that it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The FDA has determined that the impurity in some ranitidine products increases over time even under normal storage conditions, and when stored at higher than room temperatures, the NDMA levels increase significantly and may result in consumer exposure to unacceptable levels of this impurity.
As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S.
Chaffin Luhana represents thousands of consumers who used Zantac/ranitidine and were diagnosed with cancer.
Firm Co-Founder and Partner, Roopal Luhana, has been appointed by Robin L. Rosenberg in the U.S. District Court for the Southern District of Florida to the Plaintiffs’ Practices and Procedures Committee in the Zantac MDL. This committee is one of two interim Plaintiff committees appointed to organize the initial stages of this national litigation. We will continue to work diligently to move this important litigation forward on behalf of those who allegedly developed cancer because of this drug.